Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Fennec Pharmaceuticals (FENC) over the last 7 years, with Q3 2025 value amounting to $3.2 million.

  • Fennec Pharmaceuticals' Non-Current Assets rose 23441.42% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 23441.42%. This contributed to the annual value of $822000.0 for FY2024, which is 1360000.0% up from last year.
  • Fennec Pharmaceuticals' Non-Current Assets amounted to $3.2 million in Q3 2025, which was up 23441.42% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Non-Current Assets registered a high of $4.1 million during Q2 2025, and its lowest value of $6000.0 during Q4 2023.
  • In the last 5 years, Fennec Pharmaceuticals' Non-Current Assets had a median value of $211000.0 in 2022 and averaged $907941.2.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Non-Current Assets tumbled by 9715.64% in 2023, and later skyrocketed by 1360000.0% in 2024.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Non-Current Assets stood at $35000.0 in 2021, then soared by 502.86% to $211000.0 in 2022, then crashed by 97.16% to $6000.0 in 2023, then skyrocketed by 13600.0% to $822000.0 in 2024, then soared by 288.93% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $4.1 million for Q2 2025, and $3.4 million during Q1 2025.